Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Zh Nevrol Psikhiatr Im S S Korsakova ; 122(7. Vyp. 2): 52-59, 2022.
Artigo em Russo | MEDLINE | ID: mdl-35912557

RESUMO

OBJECTIVE: To analyze the expression of several previously unstudied miRNAs from the DLK1-DIO3 locus in peripheral blood mononuclear cells (PBMC) and in CD14+ and CD4+ cell subpopulations in patients with relapsing-remitting multiple sclerosis (RRMS) and healthy individuals. MATERIAL AND METHODS: MiRNA expression analysis was performed in PBMC, CD14+, and CD4+ cells of 14 patients who did not take immunomodulatory drugs, and 14 individuals without autoimmune and inflammatory diseases by reverse transcription followed by real-time PCR. RESULTS: Expression levels of 10 miRNAs selected based on different criteria were significantly higher in PBMC in men with RRMS compared to healthy men; in women, their expression did not change in a similar comparison. No mass unidirectional changes in the expression of these miRNAs in RRMS men were observed in CD14+ and CD4+ cells. High consistency in the expression of miRNA pairs was also not found. CONCLUSIONS: The analysis of PBMC showed the involvement of 10 more miRNAs encoded by genes from the DLK1-DIO3 locus in the development of RRMS. The main observed effect of the increase in the expression levels of these miRNAs in men with RRMS compared with healthy men is not achieved due to the contribution of CD14+ and CD4+ cells. This opens up possibilities for studying the involvement of miRNAs in other PBMC subpopulations in the pathological processes in RRMS.


Assuntos
MicroRNAs , Esclerose Múltipla Recidivante-Remitente , Esclerose Múltipla , Linfócitos T CD4-Positivos/metabolismo , Proteínas de Ligação ao Cálcio/genética , Feminino , Humanos , Leucócitos Mononucleares/metabolismo , Masculino , Proteínas de Membrana/genética , MicroRNAs/genética , Esclerose Múltipla/genética , Esclerose Múltipla Recidivante-Remitente/genética
2.
Zh Nevrol Psikhiatr Im S S Korsakova ; 121(7. Vyp. 2): 99-103, 2021.
Artigo em Russo | MEDLINE | ID: mdl-34387455

RESUMO

Comorbidities of extrapyramidal disorders and multiple sclerosis (MS) are rare. The chance of a combination of MS and Parkinson's disease (PD) is less than 1 in 12.5 million. In total, 42 cases of joint development of these disorders are described in the literature. All described patients had no initial changes in the basal ganglia on MRI, and the development of MS was diagnosed after 1-8 years. Possible common links in the pathogenesis of neurodegenerative disease and MS, as well as the cumulative effect of the two diseases on the severity of axonal degeneration and neuronal loss are discussed. A description of a clinical case of a combination of early onset PD and relapsing-remitting multiple sclerosis is presented.


Assuntos
Esclerose Múltipla Recidivante-Remitente , Esclerose Múltipla , Doenças Neurodegenerativas , Doença de Parkinson , Comorbidade , Humanos , Esclerose Múltipla Recidivante-Remitente/diagnóstico por imagem , Esclerose Múltipla Recidivante-Remitente/epidemiologia , Doença de Parkinson/diagnóstico , Doença de Parkinson/epidemiologia
3.
Zh Nevrol Psikhiatr Im S S Korsakova ; 120(7. Vyp. 2): 7-12, 2020.
Artigo em Russo | MEDLINE | ID: mdl-32844624

RESUMO

Increased sensitivity and availability of magnetic resonance imaging (MRI) in neurological routine practice led to the fact that more and more experts began to encounter changes typical for multiple sclerosis (MS) according to MRI in the absence of anamnestic and clinical indications of damage to the central nervous system (CNS). This nosological form has been defined as a radiologically isolated syndrome (RIS). More and more RIS cases convert to MS (up to 30% in the first 5 years after RIS diagnosis). At the moment, there are no biological markers that allow combining RIS and MS into one pathological process and early treatment with disease-modifying drugs (DMT). Prospective studies are actively being conducted to identify demographic, clinical, neuroimaging and biochemical conversion predictors. The identification of the molecular biological RIS features, combining these changes with MS, is an urgent scientific task and will allow timely initiation of therapy of the pathological process already at the subclinical stage.


Assuntos
Doenças Desmielinizantes , Esclerose Múltipla , Humanos , Imageamento por Ressonância Magnética , Prognóstico , Estudos Prospectivos
4.
Zh Nevrol Psikhiatr Im S S Korsakova ; 119(10. Vyp. 2): 28-34, 2019.
Artigo em Russo | MEDLINE | ID: mdl-31934986

RESUMO

Biogenic amines are key mediators of neuroimmune interaction and may influence on multiple sclerosis (MS) pathogenesis and MS course. At the same time, the role of biogenic amines in immunoregulation of early stages of demyelination, in particular clinically isolated syndrome (CIS) and radiologically isolated syndrome (RIS) is still unclear. This literature review addresses a role of norepinephrine in the regulation of neuroimmune interactions in the early stages of the demyelination. Neuropsychological disorders, immunological characteristics, gut-brain axis as well as the role of norepinephrine in these interactions in patients with CIS, RIS and early MS are discussed.


Assuntos
Microbioma Gastrointestinal , Esclerose Múltipla/microbiologia , Esclerose Múltipla/patologia , Fibras Nervosas Mielinizadas/patologia , Norepinefrina/metabolismo , Encéfalo/patologia , Encéfalo/fisiopatologia , Humanos , Esclerose Múltipla/imunologia , Esclerose Múltipla/metabolismo
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...